Novel anti-inflammatory slows progression of MS in mice
When delivered intranasally, the anti-inflammatory drug VX-765 prevented axon demyelination and loss in a murine model of multiple sclerosis (MS).
List view / Grid view
When delivered intranasally, the anti-inflammatory drug VX-765 prevented axon demyelination and loss in a murine model of multiple sclerosis (MS).
An analysis reveals that in comparison to other inflammatory diseases such as cytokine-release syndrome (CRS) and sepsis, the levels of cytokines in severely ill COVID-19 patients is low.
Researchers reveal that SARS-CoV-2 is more infectious than SARS-CoV because it can use both ACE2 and neuropilin-1 to infect cells.
Scientists who developed the E22W42 DC vaccine suggest it could be safer and more effective than previous anti-amyloid Alzheimer’s therapies.
Researchers have found that CBD reduces inflammation in the lungs of COVID-19 mouse models by increasing levels of the apelin peptide.
Researchers have mapped 90 percent of the human proteome, which could inform the development of new medicines.
A simple co-culture assay that can assess anti-tumour T-cell cytotoxicity via luminescence and flow cytometry has been created.
Scientists suggest targeting the SARS-CoV-2 papain-like protease (PLpro) with inhibitors could prevent the spread of infection.
Topical delivery of a small interfering RNA (siRNA) using an ionic liquid complex significantly reduced levels of inflammatory cytokines and symptoms of psoriasis.
Researchers have implicated long non-coding RNAs in tumour progression and suggest they may be potential drug targets for cancers with p53 mutations.
Researchers suggest that targeting host proteins with drugs, rather than directly targeting enzymes or proteins on SARS-CoV-2 and related coronaviruses, could improve outcomes.
Scientist identified the mechanism through which temporal lobe epileptic seizures are sparked and that D-serine can interfere with this process, preventing seizures.
Researchers have found that the level of antibodies in the serum of SARS-CoV-2 patients correlated with disease severity.
A team has identified 219 molecules and genes that influence the severity of COVID-19 in patients, providing information that could aid the development of therapeutics.
Researchers have shown that an siRNA nanomedicine can target BACE1 in a mouse model of Alzheimer's, restoring cognitive capacity.